Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 202.55$. Average daily volumn in 3 months 1.15M. Market cap 29.87B



Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 203.94$. Total volume : 1.19M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price
203.94$
Change
-1.29
Volume
1.19M

Previous Close205.23
Open203.58
Day Range200.40-206.89
Bid201.42 x 900
Ask205.20 x 1k
Volume1.19M
Average Volume1.15M
Market Cap29.87B
Beta0.42
52 Week Range187.16-372.12
Trailing P/E20.60
Foward P/E12.75
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).


Loading ...



Organization

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
29.87B
Revenue:
10.98B
Total Assets:
23.88B
Total Cash:
2.26B


News about "Biogen Inc."

creative-financial-designs-inc-adv-has-38000-stock-holdings-in-biogen-inc-nasdaqbiib-image

Creative Financial Designs Inc. ADV Has $38,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Source from : Defense World - 8 hours ago

Creative Financial Designs Inc. ADV cut its position in shares of Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 98.2% during the first quarter, according to the company in its most recent disclosure with ...See details»


advisornet-financial-inc-sells-192-shares-of-biogen-inc-nasdaqbiib-image

AdvisorNet Financial Inc Sells 192 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : Defense World - 9 hours ago

AdvisorNet Financial Inc cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 23.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange ...See details»


exclusive-has-biotech-bottomed-nyse-executive-floor-director-says-biogen-and-these-3-stocks-look-poised-to-outperform-image

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform

Source from : Business Insider - 1 days ago

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.See details»


biogen-to-reimburse-employees-who-travel-100-plus-miles-for-abortion-image

Biogen to reimburse employees who travel 100-plus miles for abortion

Source from : The Business Journals - 1 days ago

In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access ...See details»


ritholtz-wealth-management-sells-233-shares-of-biogen-inc-nasdaqbiib-image

Ritholtz Wealth Management Sells 233 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 1 days ago

Ritholtz Wealth Management lowered its holdings in Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»


Biogen stops clinical trial tracking Aduhelm

Source from : MarketWatch on MSN.com - 7 days ago

Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»


ibm-retirement-fund-trims-stock-position-in-biogen-inc-nasdaqbiib-image

IBM Retirement Fund Trims Stock Position in Biogen Inc. (NASDAQ:BIIB)

Source from : ETF Daily News - 4 days ago

IBM Retirement Fund lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the ...See details»


five-things-you-need-to-know-and-closing-the-wealth-gap-image

Five things you need to know, and closing the wealth gap

Source from : The Business Journals - 1 days ago

Good morning, Boston. Here are the five most important things you need to know to start your workday, plus Sally Ride, another venture fund, a new college president, and gathering together to solve ...See details»


biogen-citing-insurance-challenges-shutters-one-of-its-aduhelm-studies-image

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

Source from : BioPharma Dive - 8 days ago

The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.See details»


when-the-price-of-biogen-inc-common-stock-biib-talks-people-listen-image

When the Price of Biogen Inc. Common Stock BIIB Talks, People Listen

Source from : news.stocktradersdaily - 7 days ago

Buy BIIB over 195.67 target n/a stop loss @ 195.1. Details; The technical summary data tells us to buy BIIB near 195.67, but there is no curren ...See details»


biogen-pulls-plug-on-aduhelm-real-world-study-on-coverage-woes-image

Biogen pulls plug on Aduhelm real-world study on coverage woes

Source from : Seeking Alpha - 7 days ago

Alzheimer's disease therapy Aduhelm woes seem to continue as the company terminated a study calledย ICARE AD, which was started to collect real-world data on ...See details»


Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?

Source from : Nasdaq - 29 days ago

It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...See details»


biogen-secures-tecfidera-patent-in-eu-until-2028-generics-not-likely-image

Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely

Source from : Multiple Sclerosis News Today - 8 days ago

Biogen's new patent for its oral MS medication Tecfidera expires in 2028 โ€“ so generics likely will not enter the European market until then.See details»


Which Biotech Stock is the Street More Bullish on?

Source from : Nasdaq - 2 days ago

Amid the ongoing market downturn, investors can look for biotech companies with lucrative growth potential that are trading at attractive levels as per Wall Street analysts. Using the Stock Comparison ...See details»